Home » Newsletters » BioWorld

BioWorld

Oct. 4, 2000

View Archived Issues

Syrrx Raises $20M In 2nd Round To Advance Structural Genomics

Trimeris, Roche Move Fusion Inhibitor Into Phase III Studies

Other News To Note

Ill-Fated New Drug Study Aimed At Autoimmune Root of Multiple Sclerosis Netted Some Lessons

Informax IPO Garners $80M For Bioinformatics Platform

Affymetrix Forms $100M Firm Expected To Read 50 Genomes